Previous 10 | Next 10 |
Generated record quarterly revenue of $69 million in 2Q22, an increase of 50% compared to 2Q21 Fiscal year 2022 revenue guidance increased to $253 million, an increase of 40% compared to fiscal year 2021 Axonics, Inc. (Nasdaq: AXNX), a global medical technolo...
ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model looks to “Grow Markets and Take Market Share” targeting an ...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will ...
Axonics (NASDAQ:AXNX) said it filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulation implantable neurostimulator (INS). The fourth gen rechargeable INS reduces the time needed by a patient to recharge their implanted device to onc...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval supplement with the FDA for its fourth generation rechargeable sacral neuromodulatio...
Axonics is a high-growth medical device play with strong revenue growth drivers. The company’s rechargeable SNM system generates the vast majority of its sales. Long-term investors can buy the company’s shares during pullbacks to maximize their gain. For furthe...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In what turned out to be a challenging first quarter, Baron Discovery Fund (the “Fund”) decreased 16.30% (I...
Axonics, Inc. (AXNX) Q1 2022 Earnings Conference Call May 5, 2022 04:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Cecilia ...
Axonics Modulation Technologies press release (NASDAQ:AXNX): Q1 GAAP EPS of -$0.50 beats by $0.13. Revenue of $48.42M (+40.9% Y/Y) beats by $3.05M. FY22 Outlook: Total company revenue of $238M, an increase of 32% compared to FY21 revenue. This compares to prior revenue guidance of $234M;...
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. “We are pleased with this qu...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...